[go: up one dir, main page]

SI2114405T1 - Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona - Google Patents

Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Info

Publication number
SI2114405T1
SI2114405T1 SI200731644T SI200731644T SI2114405T1 SI 2114405 T1 SI2114405 T1 SI 2114405T1 SI 200731644 T SI200731644 T SI 200731644T SI 200731644 T SI200731644 T SI 200731644T SI 2114405 T1 SI2114405 T1 SI 2114405T1
Authority
SI
Slovenia
Prior art keywords
methanone
piperazin
methanesulfonyl
trifluoro
pyridin
Prior art date
Application number
SI200731644T
Other languages
English (en)
Inventor
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2114405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2114405T1 publication Critical patent/SI2114405T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI200731644T 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona SI2114405T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1
EP07857734.3A EP2114405B1 (en) 2006-12-28 2007-12-18 methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone

Publications (1)

Publication Number Publication Date
SI2114405T1 true SI2114405T1 (sl) 2015-06-30

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731644T SI2114405T1 (sl) 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (sl)
EP (1) EP2114405B1 (sl)
JP (1) JP4799666B2 (sl)
KR (1) KR101130146B1 (sl)
CN (1) CN101573114A (sl)
AR (1) AR064545A1 (sl)
AU (1) AU2007341356B2 (sl)
BR (1) BRPI0720829B8 (sl)
CA (1) CA2673667A1 (sl)
CL (1) CL2007003830A1 (sl)
CO (1) CO6190613A2 (sl)
CR (1) CR10846A (sl)
CY (1) CY1116350T1 (sl)
DK (1) DK2114405T3 (sl)
EC (1) ECSP099471A (sl)
ES (1) ES2535040T3 (sl)
HR (1) HRP20150573T1 (sl)
HU (1) HUE025032T2 (sl)
MA (1) MA31029B1 (sl)
MX (1) MX2009006859A (sl)
MY (1) MY188367A (sl)
NO (1) NO342150B1 (sl)
NZ (1) NZ577502A (sl)
PE (1) PE20081556A1 (sl)
PL (1) PL2114405T3 (sl)
PT (1) PT2114405E (sl)
RS (1) RS53910B1 (sl)
RU (1) RU2463295C2 (sl)
SI (1) SI2114405T1 (sl)
TW (1) TWI388552B (sl)
UA (1) UA100232C2 (sl)
WO (1) WO2008080821A1 (sl)
ZA (1) ZA200904423B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673667A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1
EP2400848A4 (en) * 2009-02-26 2012-07-25 Thar Pharmaceuticals Inc CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
JP2015518841A (ja) * 2012-05-25 2015-07-06 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ １，５−ジメチル−６−チオキソ−３−（２，２，７−トリフルオロ−３−オキソ−４−（プロピ−２−イニル）−３，４−ジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−６−イル）−１，３，５−トリアジナン−２，４−ジオンの結晶形態Ｂ
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CN115279372A (zh) 2020-01-09 2022-11-01 迪斯克医药公司 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
JP7096957B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
EP4337199A4 (en) * 2021-05-14 2025-03-19 Disc Medicine, Inc. Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents
US20240390362A1 (en) * 2021-05-27 2024-11-28 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
DK1656361T3 (da) * 2003-08-11 2008-05-05 Hoffmann La Roche Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer
CA2673667A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1

Also Published As

Publication number Publication date
NO342150B1 (no) 2018-04-03
TWI388552B (zh) 2013-03-11
AR064545A1 (es) 2009-04-08
US20110295007A1 (en) 2011-12-01
TW200833677A (en) 2008-08-16
ECSP099471A (es) 2009-07-31
ZA200904423B (en) 2010-05-26
RU2009124113A (ru) 2011-02-10
BRPI0720829A2 (pt) 2014-02-25
KR101130146B1 (ko) 2012-03-28
AU2007341356A1 (en) 2008-07-10
MX2009006859A (es) 2009-07-03
HRP20150573T1 (xx) 2015-07-03
US20120309969A1 (en) 2012-12-06
WO2008080821A1 (en) 2008-07-10
US8039473B2 (en) 2011-10-18
PL2114405T3 (pl) 2015-08-31
CA2673667A1 (en) 2008-07-10
NZ577502A (en) 2012-02-24
EP2114405A1 (en) 2009-11-11
BRPI0720829B1 (pt) 2020-04-07
KR20090094166A (ko) 2009-09-03
NO20092358L (no) 2009-06-22
BRPI0720829B8 (pt) 2021-05-25
JP4799666B2 (ja) 2011-10-26
PT2114405E (pt) 2015-06-02
RS53910B1 (sr) 2015-08-31
RU2463295C2 (ru) 2012-10-10
ES2535040T3 (es) 2015-05-04
CL2007003830A1 (es) 2008-07-11
EP2114405B1 (en) 2015-03-11
CY1116350T1 (el) 2017-03-15
AU2007341356B2 (en) 2013-08-29
MY188367A (en) 2021-12-06
MA31029B1 (fr) 2009-12-01
UA100232C2 (uk) 2012-12-10
US20100311971A1 (en) 2010-12-09
CR10846A (es) 2009-08-12
US20080214561A1 (en) 2008-09-04
CO6190613A2 (es) 2010-08-19
HUE025032T2 (en) 2016-02-29
JP2010514725A (ja) 2010-05-06
PE20081556A1 (es) 2008-11-28
US20130197225A1 (en) 2013-08-01
CN101573114A (zh) 2009-11-04
DK2114405T3 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
SI2114405T1 (sl) Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
CY2020030I1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιλο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
ZA200810017B (en) 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
BRPI0716880A2 (pt) Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
ZA200802488B (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
CU24179B1 (es) SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
SG173735A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2005105096A3 (en) Fused heterocyclic compounds
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
EP1968578A4 (en) POLYMORPHIC AND AMORPHOUS FORMS OF 5-AMINO-L- [2,6-DICHLORO-4- (TRIFLUOROMETHYL) PHENYL] -4- [(TRIFLUOROMETHYL) SULFINYL] -IH-PYRAZOLE-3-CARBONITRIL
ZA200801813B (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
WO2005113526A3 (en) Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
SI1718593T1 (sl) Stereoselektivna sinteza 4,4-disubstituirane cikloheksanpropanojske kisline
WO2007016139A3 (en) Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene
IL206613A0 (en) Process for the production of 4-(substituted phenyl) hexahydropyrido[2,1-c][1,4]oxazin-6-one
FR2867687B1 (fr) Procede d'obtention d'une composition desinfectante, composition obtenue
AU2007905335A0 (en) A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
AU2013203234A1 (en) Polymorphs and amorphous forms of 5-amino-1-[2,6- dichloro-4-(trifluoromethyl)phenyl]-4- [(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile